In addition, with the development of AD diagnostic criteria, the latest research framework focuses on the diagnosis of AD and MCI using biomarkers, including beta amyloid deposition, pathological tau and neurodegeneration, called AT (N) biomarker system66, and the system accepts novel biomarkers added to existing frameworks. The gene discussed is MAPT; the disease is Alzheimer disease.